Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $3.7 million.

  • SAB Biotherapeutics' Accumulated Expenses rose 11.20% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 11.20%. This contributed to the annual value of $4.2 million for FY2024, which is 22.65% up from last year.
  • SAB Biotherapeutics' Accumulated Expenses amounted to $3.7 million in Q3 2025, which was down 27.11% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Accumulated Expenses registered a high of $5.1 million during Q2 2025, and its lowest value of $80,000 during Q1 2021.
  • For the 3-year period, SAB Biotherapeutics' Accumulated Expenses averaged around $2.8 million, with its median value being $3.3 million (2024).
  • Examining YoY changes over the last 5 years, SAB Biotherapeutics' Accumulated Expenses showed a top increase of 748.57% in 2022 and a maximum decrease of 24.15% in 2022.
  • SAB Biotherapeutics' Accumulated Expenses (Quarterly) stood at $674,858 in 2021, then decreased by 24.15% to $511,849 in 2022, then skyrocketed by 564.32% to $3.4 million in 2023, then increased by 22.65% to $4.2 million in 2024, then climbed by 11.20% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $5.1 million for Q2 2025, and $4.0 million during Q1 2025.